Amalgamated Bank Has $4.73 Million Position in Exelixis, Inc. (NASDAQ:EXEL)

Amalgamated Bank boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 142,147 shares of the biotechnology company’s stock after buying an additional 2,435 shares during the period. Amalgamated Bank’s holdings in Exelixis were worth $4,733,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in EXEL. Raymond James & Associates raised its holdings in shares of Exelixis by 118.2% in the 3rd quarter. Raymond James & Associates now owns 239,661 shares of the biotechnology company’s stock worth $6,219,000 after acquiring an additional 129,805 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Exelixis by 18.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,317 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 1,620 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Exelixis by 4.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 143,547 shares of the biotechnology company’s stock valued at $3,725,000 after purchasing an additional 6,355 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Exelixis by 7.5% during the third quarter. DekaBank Deutsche Girozentrale now owns 429,690 shares of the biotechnology company’s stock valued at $11,028,000 after buying an additional 30,000 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in Exelixis by 1.2% during the third quarter. State of Alaska Department of Revenue now owns 126,842 shares of the biotechnology company’s stock worth $3,290,000 after buying an additional 1,455 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on EXEL. Citigroup raised their price objective on Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Truist Financial raised their price target on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Stephens reaffirmed an “equal weight” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. Finally, Wells Fargo & Company lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 target price for the company. in a report on Monday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.24.

Exelixis Stock Up 0.3 %

Shares of NASDAQ:EXEL opened at $37.65 on Friday. The firm has a market capitalization of $10.54 billion, a PE ratio of 21.27, a P/E/G ratio of 1.13 and a beta of 0.53. The company has a 50-day moving average price of $34.42 and a two-hundred day moving average price of $31.54. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $38.43.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Activity at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now owns 303,310 shares of the company’s stock, valued at $11,216,403.80. The trade was a 14.79 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mary C. Beckerle sold 12,210 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,807 shares of company stock worth $4,126,373. 2.85% of the stock is owned by company insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.